A study presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting in America has shown that MS patients of African descent might better benefit from treatment of Lemtrada compared to Rebif – with lower rates of relapses evident over five years of treatment.
In the study, Patients Of African Descent With Active Relapsing-Remitting Multiple Sclerosis Demonstrate Clinical And Radiologic Benefits with Alemtuzumab (Lemtrada) Over Five Years, relapsing-remitting MS (RRMS) patients not previously treated and patients who did not respond adequately to treatment, were enrolled in the study.
Patients received one course of Lemtrada per year, or Rebif, during the first two years. After that, Lemtrada was administered when patients experienced a relapse or had increased lesion activity on magnetic resonance imaging (MRI) brain scans.
Supported by Genzyme and Bayer HealthCare Pharmaceuticals, the study was performed by investigators from the Multiple Sclerosis Treatment Centre of Dallas in collaboration with other national MS centres. The core study included 46 patients of African descent. Among them, 35 received Lemtrada and 11 received Rebif.
Average annual relapse rates for the first two years were 0.19 for patients on Lemtrada and 0.62 with Rebif, further improving to 0.16 in the Lemtrada group when calculating the average in a follow-up period of five years.
Lemtrada did not give rise to any serious adverse events linked to the treatment. The rate of serious infection was similar among the patients of African descent and the rest of the study group.
The authors concluded that patients of African descent are likely more responsive to MS treatment with Lemtrada, compared to Rebif.
#CMSC16 – Study Aims to Improve MS Care by Considering Patients’ Perspectives
Source: Multiple Sclerosis News Today, 06 June 2016, Magdalena Kegal